Atrial natriuretic peptide and prostacyclin synergistically mediate hyperfiltration and hyperperfusion of diabetic rats

Diabetes. 1992 Apr;41(4):533-8. doi: 10.2337/diab.41.4.533.

Abstract

The relative contribution of atrial natriuretic peptide (ANP) and vasodilatory prostaglandins to hyperfiltration in Wistar rats with experimental diabetes was studied 6-8 wk after streptozocin injection. Plasma levels of immunoreactive ANP were significantly higher (P less than 0.01) in hyperglycemic diabetic (72.9 +/- 11.7 pg/ml) than in normoglycemic diabetic (44.8 +/- 8.6 pg/ml) or nondiabetic (40.0 +/- 6.8 pg/ml) rats. Blocking endogenous ANP by specific ANP-antiserum infusion reduced significantly (P less than 0.01) glomerular filtration rate (GFR) and renal plasma flow (RPF) of hyperglycemic rats compared with preinfusion values (1.23 +/- 0.06-1.02 +/- 0.04; 2.87 +/- 0.25-2.40 +/- 0.10 ml.min-1.100 g-1, respectively). However, correction of hyperfiltration and hyperperfusion was only partial (nondiabetic rats GFR 0.85 +/- 0.07; RPF 2.27 +/- 0.13 ml.min-1.100 g-1). Because diabetic rats with hyperglycemia also had an increased urinary excretion of prostacyclin metabolite 6-keto-prostaglandin F1 alpha (220.6 +/- 62.8 ng/24 h) compared with nondiabetic rats (51.2 +/- 2.7 ng/24 h), we wondered whether excessive prostacyclin formation contributed to hyperfiltration and hyperperfusion in this setting. Indomethacin infusion partially reduced GFR (1.25 +/- 0.07 to 1.06 +/- 0.07 ml.min-1.100 g-1, P less than 0.05) and RPF (2.85 +/- 0.11 to 2.46 +/- 0.12 ml.min-1.100 g-1, P less than 0.01) in diabetic rats. The combined infusion of ANP antiserum and indomethacin normalized GFR and RPF in diabetic rats with hyperglycemia (1.27 +/- 0.05 to 0.88 +/- 0.05 and 2.84 +/- 0.10 to 2.22 +/- 0.06 ml.min-1.100 g-1, respectively; P less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Atrial Natriuretic Factor / administration & dosage
  • Atrial Natriuretic Factor / blood
  • Atrial Natriuretic Factor / pharmacology*
  • Diabetes Mellitus, Experimental / blood
  • Diabetes Mellitus, Experimental / physiopathology*
  • Diabetes Mellitus, Experimental / urine
  • Drug Synergism
  • Epoprostenol / administration & dosage
  • Epoprostenol / pharmacology*
  • Epoprostenol / urine
  • Glomerular Filtration Rate / drug effects
  • Glomerular Filtration Rate / physiology
  • Hyperglycemia / blood
  • Hyperglycemia / physiopathology
  • Indomethacin / administration & dosage
  • Indomethacin / pharmacology
  • Infusions, Intravenous
  • Injections, Intravenous
  • Kidney / blood supply
  • Kidney / drug effects
  • Kidney / physiology*
  • Male
  • Radioimmunoassay
  • Rats
  • Rats, Inbred Strains
  • Regional Blood Flow / drug effects
  • Regional Blood Flow / physiology
  • Streptozocin

Substances

  • Streptozocin
  • Atrial Natriuretic Factor
  • Epoprostenol
  • Indomethacin